Indications and medication precautions of TrelegyEllipta, GlaxoSmithKline GSK Türkiye
Trelegy Ellipta inhalation powder is a triple inhalation formulation containing fluticasone furoate, remdesivir bromide, and vilantol, used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The indications are clear, and medication should pay attention to inhalation methods, adverse reaction monitoring, and medication for special populations.
1. Indications
(1) Chronic obstructive pulmonary disease (COPD)
Long term maintenance treatment for COPD patients, including chronic bronchitis and emphysema, can reduce acute exacerbations and improve lung function.
(2) Asthma
Used for maintenance treatment of asthma patients aged 18 and above, it should be used in combination with other asthma control drugs and is not suitable for relieving acute bronchospasm.
2. Medication precautions
(1) Correct inhalation method
Before use, it is necessary to read the instruction manual and master the operating skills of the Ellipta inhaler. Rinsing mouth after inhalation can reduce the risk of oral candidiasis infection.
(2) Adverse reaction monitoring
Common adverse reactions include headache, throat irritation, and cough. Be alert to the occurrence of serious adverse reactions such as pneumonia and cardiovascular events.
(3) Contraindications
Prohibited for individuals allergic to milk protein or formulation ingredients. Do not use as emergency medication during severe asthma attacks.
(4) Medication for special populations
During pregnancy, weigh the pros and cons, and use with caution during lactation. Patients with liver dysfunction do not need to adjust the dosage, while those with severe renal dysfunction should be cautious.
(5) Drug interactions
The combination with strong CYP3A4 inhibitors may increase systemic exposure to fluticasone furoate, and adrenal suppression symptoms need to be monitored.
(6) Acute exacerbation treatment
When acute respiratory symptoms worsen, it is necessary to increase the use of short acting bronchodilators, and the dosage of this product should not be increased.
Disclaimer：《Indications and medication precautions of TrelegyEllipta, GlaxoSmithKline GSK Türkiye》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！